Skip to main content

Advertisement

SpringerLink
Log in

Sipuleucel-T

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jemal, A. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  2. Oh, W. K. & Schurko, B. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506–507 (2008).

    Article  Google Scholar 

  3. Patel, P. H. & Kockler, D. R. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42, 91–98 (2008).

    Article  Google Scholar 

  4. Gilboa, E. The promise of cancer vaccines. Nature Rev. Cancer 4, 401–411 (2004).

    Article  CAS  Google Scholar 

  5. US Food and Drug Administration. FDA labelling information — Provenge. FDA website [online], (2010).

  6. Small, E. J. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894–3903 (2000).

    Article  CAS  Google Scholar 

  7. Burch, P. A. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175–2182 (2000).

    CAS  PubMed  Google Scholar 

  8. Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).

    Article  CAS  Google Scholar 

  9. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    Article  CAS  Google Scholar 

  10. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1488–1490 (2004).

    Article  Google Scholar 

  11. Beer, T. M. et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J. Clin. Oncol. 25, 18S (2007).

    Article  Google Scholar 

  12. Kelly, W. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J. Clin. Oncol. 28, 344s (2010).

    Google Scholar 

  13. IMS MIDAS (2009).

  14. Reams, A. & Andrews, M. J. Biotechnology equity research report. Wells Fargo Securities (19 May 2010).

  15. Kasimov, C., Ashiya M. & Jay, K. Equity research report. JP Morgan North America (11 May 2010).

Download references

Author information

Authors and Affiliations

  1. Celestia S. Higano is at the Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, USA. thigano@u.washington.edu,

    Celestia S. Higano

  2. Eric J. Small is at the Department of Medicine and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.,

    Eric J. Small

  3. Paul Schellhammer is at the Department of Urology, Eastern Virginia Medical School, USA.,

    Paul Schellhammer

  4. Uma Yasothan and Steven Gubernick are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan & Steven Gubernick

  5. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

  6. Philip W. Kantoff is at the Department of Medicine, Dana–Farber Cancer Institute, Harvard Medical School, USA. Philip_Kantoff@dfci.harvard.edu,

    Philip W. Kantoff

Authors
  1. Celestia S. Higano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric J. Small
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Schellhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven Gubernick
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philip W. Kantoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Higano, C., Small, E., Schellhammer, P. et al. Sipuleucel-T. Nat Rev Drug Discov 9, 513–514 (2010). https://doi.org/10.1038/nrd3220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3220

  • Springer Nature Limited

This article is cited by

Search

Navigation